Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4965-4972

  Hartford, Christine ^a   Vasquez, Erick ^a   Schwab, Matthias ^a,c,d   Edick, Mathew J ^a,b   Rehg, Jerold E ^a   Grosveld, Gerard ^a   Pui, Ching Hon ^a,b   Evans, William E ^a,b   Relling, Mary V ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DRUG METABOLITE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; NUCLEOTIDE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CANCER EPIDEMIOLOGY; CHILD; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TARGETING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; KNOCKOUT MOUSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; WEIGHT REDUCTION;

6-MERCAPTOPURINE; ANIMALS; CHILD; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHYLTRANSFERASES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMORPHISM, GENETIC; PURINES; THIOGUANINE;

EID: 34250356290     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3508     Document Type: Article

References (50)

1. McLeod H, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-72.
2. Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine 5-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996;6:279-90.
3. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
4. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
5. Balis FM, Adamson PC. Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Inst 1999;91:1983-5.
6. Otterness DM, Weinshilboum RM. Mouse thiopurine methyltransferase pharmacogenetics: monogenic inheritance. J Pharmacol Exp Ther 1987;240:817-24.
7. Vuchetich JP, Weinshilboum RM, Price RA. Segregation analysis of human red blood cell thiopurine methyltransferase activity. Genet Epidemiol 1995;12:1-11.
8. Weinshilboum RM. Human pharmacogenetics of methyl conjugation. Fed Proc 1984;43:2303-7.
9. Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992;22:1055-71.
10. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85:1897-902.
11. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14: 407-17.
12. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
13. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62: 60-73.
14. McLeod HR, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15-20.
15. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993;341:436.
16. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985-9.
17. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-8.
18. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005;293:1485-9.
19. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12:346-52.
20. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356: 285-90.
21. Thompson J, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999;86:1080-6.
22. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810-6.
23. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004;26:186-91.
24. Scheuermann TH, Lolis E, Hodsdon ME. Tertiary structure of thiopurine methyltransferase from Pseudomonas syringae, a bacterial orthologue of a polymorphic, drug-metabolizing enzyme. J Mol Biol 2003; 333:573-85.
25. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 1997;94:6444-9.
26. Tai HL, Fessing M, Bonten EJ, et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999;9:641-50.
27. Wang L, Sullivan W, Toft D, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003;13:555-64.
28. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynetski EY, Evans WE. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther 1998;64:46-51.
29. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
30. Krynetski EY, Fessing MY, Yates CR, Sun D, Schuetz JD, Evans WE. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PACI genomic library. Pharm Res 1997;14:1672-8.
31. Fessing MY, Belkov VM, Krynetski EY, Evans WE. Molecular cloning and functional characterization of the cDNA encoding the murine thiopurine S-methyltransferase (TPMT). FEBS Lett 1998;424:143-5.
32. Hernandez JS, Van Loon JA, Otterness DM, Weinshilboum RM. Mouse thiopurine methyltransferase pharmacogenetics: correlation of immunoreactive protein and enzymatic activity. J Pharmacol Exp Ther 1990; 252:568-73.
33. Watters JW, Zhang W, Meucci MA, Hou W, Ma MK, McLeod HL. Analysis of variation in mouse TPMT genotype, expression and activity. Pharmacogenetics 2004;14:247-54.
34. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148-59.
35. Masson E, Synold TW, Relling MV, et al. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia 1996;10:56-60.
36. Dervieux T, Chu YQ, Su E, Pui CH, Evans WE, Relling MV. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblast following mercaptopurine. Clin Chem 2002;48:161-8.
37. Su Y, Hon YY, Chu Y, Van de Poll ME, Relling MV. Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection. J Chromatogr B Biomed Sci Appl 1999;732:459-68.
38. Herrlinger KR, Fellermann K, Fischer C, et al. Thioguanine-nucleotides do not predict efficacy of thioguanine in Crohn's disease. Aliment Pharmacol Ther 2004;19:1269-76.
39. Relling MV, Pui CH, Cheng C, Evans WEE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006;107:843-4.
40. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
41. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998; 42:266-72.
42. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68:186-90.
43. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004;75:274-81.
44. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301.
45. Berkovitch M, Matsui D, Zipursky A, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. Med Pediatr Oncol 1996;26:85-9.
46. Kontorinis N, Agarwal K, Gondolesi G, Fiel MI, O'Rourke M, Schiano TD. Diagnosis of 6 mercaptopurine hepatotoxicity post liver transplantation utilizing metabolite assays. Am J Transplant 2004;4:1539-42.
47. Heckmann JM, Lambson EM, Little F, Owne EP. Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J Neurol Sci 2005;231:71-80.
48. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15.
49. Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2003;123:100-2.
50. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.